Bristol Hopes REMS Proposal Can Overcome Safety Concerns About Belatacept

FDA's briefing documents for March 1 advisory committee review note that the kidney transplant rejection agent is linked to a potentially fatal adverse event.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet